Selskabets formål er drive handels-, industri- og finansieringsvirksomhed, herunder produktion, distribution og markedsføring af farmaceutiske, medicinske og tekniske produkter og ydelser, samt anden dertil knyttet virksomhed efter bestyrelsens skøn.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 1 mia. | 34.4 mio. | 324.8 mio. | 129.1 mio. | 139 | |
CVR: 15887478
Secondary names: ALCON DANMARK A/S, CIBA VISION DANMARK A/S
Companies in the same industry and area
CVR 41722460
CVR 39371049
CVR 39503778
CVR 40873309
CVR 31774284
Compared to 291 companies in Engroshandel med læge- og hospitalsartikler
Comparison is based on industry median values
ALCON NORDIC A/S demonstrates a solid financial trajectory with consistent revenue growth, reaching 1.01 billion DKK in 2024, up from 975 million DKK in 2023. Profitability has also improved significantly, with profits rising from 25.5 million DKK in 2023 to 34.4 million DKK in 2024, indicating enhanced operational efficiency and margin improvement. The company's equity has increased substantially, from 94.7 million DKK in 2023 to 129.1 million DKK in 2024, reflecting a strong financial foundation. However, the fluctuating profit margins over the years, particularly the dip in 2022, may warrant attention. Overall, ALCON NORDIC A/S is well-positioned within the medical supplies industry, showcasing growth potential and a strengthening balance sheet.
AI-generated summary
companydata.dk